Emergent BioSolutions Company History Timeline

(189 Jobs)
1998

The company that would become Emergent began as BioPort Corp., formed in 1998 to buy an aging, state-owned company in Lansing, Mich., that was the only licensed supplier of anthrax vaccine to the Pentagon.

2000

10-year contract awarded by HHS to deliver ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) into the Strategic National Stockpile.

2001

After the 2001 anthrax attacks that caused the deaths of five Americans and made 17 others ill, Bioport began providing its anthrax vaccine to US biodefense agencies.

2002

In response to questions about the apparent increase, Emergent said in its statement that it does not discuss drug prices in detail but asserted that “the annual cost per dose for VIGIV is about the same as it was in 2002 when factoring in inflation.”

“Factoring in inflation and the increase in shelf-life, the price of BioThrax has actually dropped since the re-licensure of the facility and the DoD contract in 2002,” the company’s statement said.

2004

In 2004, the Project BioShield Act authorized $5.6 billion for stockpiling vaccines and other medical countermeasures over the next decade.

2006

In July 2006, Emergent lobbyist John Clerici wrote an op-ed for the Baltimore Sun deriding the VaxGen drug as an “experimental anthrax vaccine from an unproven supplier.” Clerici was identified as a Washington lawyer.

Emergent spent nearly $4 million on lobbying last year alone — putting it in the upper echelon of all American companies despite its relatively small size — and about $43 million since it became publicly traded in 2006, according to data maintained by the Center for Responsive Politics.

Emergent became a publicly traded company in 2006, with its stock trading on the New York Stock Exchange under the symbol EBS.

2008

In May 2008, Emergent bought the rights to VaxGen’s anthrax drug for $2 million.

2009

Emergent’s annual revenue rose from $235 million in 2009 to $1.1 billion a decade later, much of it in contracts for the stockpile that were awarded without competitive bidding, the company’s financial filings show.

2010

By 2010, the company had more than a quarter-billion dollars in annual revenue but only one product and one main customer: the United States government.

2012

BioThrax is approved by the FDA for a five-dose, intramuscular route of administration and four-year shelf-life extension. It is later approved for a three-dose primary series in May 2012.

Bayview facility in Baltimore is acquired, later established in June 2012 as a Center for Innovation in Advanced Development and Manufacturing (CIADM) in a 25-year partnership with BARDA.

In June 2012, the government gave the company a contract to build an innovative laboratory in Baltimore — and left open the possibility of funding for future projects.

In June 2012, Emergent, along with Novartis and the Texas A&M University System was selected by the United States Department of Health and Human Services as one of the three Centers for Innovation in Advanced Development and Manufacturing.

Emergent already has a ten-year contract with the Canadian military and national health service to supply BAT that began in 2012.

2013

Emergent obtained three of those seven stockpiled drugs when it bought the Canadian firm Cangene Corp. in 2013.

The company purchased Winnipeg, Manitoba's Cangene Corporation in 2013.

BAT was first licensed in the United States in 2013 and is the only botulism antitoxin available in the United States for naturally-occurring cases of non-infant botulism.

2015

Our growth plan through 2015 is announced, establishing key drivers for pursuing growth and defining our future direction.

2016

On June 27, 2016, the US Biomedical Advanced Research and Development Authority contracted with Emergent Biosolutions to develop a vaccine for the Zika virus.

The spin-off was completed in August 2016 to form Aptevo Therapeutics.

In December 2016, Health Canada approved the purchase of Emergent's new botulism antitoxin called Botulism Antitoxin Heptavalent (BAT). The CDC and Public Health Agency of Canada both identified botulism, a type of food poisoning, as a likely biological threat.

2017

On March 31, 2017, Emergent signed a modification to its contract with BARDA to "manufacture and store bulk drug substance for its botulism antitoxin, BAT." The contract is valued at approximately $53 million for five years.

In 2017, Emergent struck a new deal to supply the stockpile with an updated version of BioThrax that cost $30 per dose, about five times what the company was paid under its original contract two decades earlier, accounting for inflation, according to previously undisclosed data obtained by The Post.

When Trump appointed him to lead ASPR in summer 2017, Kadlec was determined to shift the office’s efforts toward those goals.

The vaccine could reach stage-one clinical trials by early 2017.

An expansion of the Baltimore plant, finished in 2017, had $163 million in funding from the United States government.

2018

In March 2018, Kadlec was accompanied by Frech during a speaking engagement at the European Parliament in Brussels, a video recording from the event shows.

The Gaithersburg, Md.-based company pressed for the national stockpile and its $700 million budget to be moved under the control of Robert Kadlec, Trump’s assistant HHS secretary for preparedness and response, or ASPR. The transfer took effect in 2018.

Some of the money went toward advocacy for Narcan, the drug to counter opioid overdoses, which Emergent bought in 2018.

In 2018, Emergent acquired Adapt Pharma, the manufacturer of Narcan (naloxone), a widely used nasal spray opioid-overdose antidote, for $735 million.

Emergent purchased (also in 2018) the specialty vaccine manufacturer PaxVax, whose product line includes FDA-approved typhoid vaccine Vivotif and cholera vaccine Vaxchora, from its owner, Cerebus Capital Management, a private equity fund.

Founded
1998
Company Founded
Headquarters
Gaithersburg, MD
Company Headquarter
Founders
Fuad Hibri
Company Founders

Emergent BioSolutions Jobs Nearby

Emergent BioSolutions Jobs

Emergent BioSolutions Similar Companies

Find Jobs from Similar Companies
Personalize your job search. Where would you like to work?
0 selections

Emergent BioSolutions Similar Companies Jobs